InterMune, Inc. (NASDAQ:ITMN)

CAPS Rating: 3 out of 5

The Company is a biotech company focused on developing and commercializing innovative therapies in pulmonology and hepatology.

Recs

0
Player Avatar SnarkyApple (60.41) Submitted: 9/17/2012 4:08:56 PM : Outperform Start Price: $9.69 ITMN Score: -9.54

Shenanigans.

Report this Post Reply

Featured Broker Partners


Advertisement